17th JPIAMR transnational call for research projects - AMR Interventions 2024 (IMPACT)

General Information

• Project title: Application of encapsulated peracetic acid in woundcare and UTI applications against MDRO and biofilms
• Type: Project looking for partner
• Organisation: AGA Nanotech ltd
• Country: United Kingdom (UK)
• Career stage: Other.

Research area

• Scientific area(s) of the call:
  1. Topic 1: Design novel or improved interventions to prevent, mitigate and /or treat fungal infections, which are resistant to treatments and/or are at risk of developing resistance
• Subtopics:

• One Health Setting:

  Human Health

  Animal Health (incl. wildlife, livestock, acquatic organisms, and companion animals)

• Keywords:

  peracetic acid; woundcare; UTI; treatment; biofilms

• Brief description of your expertise / expertise you are looking for:

  AGA Nanotechnology have developed an antibiotic-free strategy to treat bacteria, MDROs, and biofilm associated infections. Utilising antimicrobial acetyl donor precursors, we can generate peracetic acid in situ at the site of infection. Leveraging our expertise in biocide research and taking learnings from cancer drug delivery we have successfully encapsulated precursor molecules in PLGA (Poly Lactic-Co-Glycolic Acid) particles. We are looking to collaborate with experts in the field of wound care, particularly chronic wounds and those interested in urinary tract infections (UTI). We have expertise in microbiology, formulation and production of particles.

• Brief description of your project / the project you would like to join:

  With the AGA encapsulated particles, we are able to reduce systemic toxicity and microbial dysbiosis by controlling the ratio of precursors ensuring the generation of peracetic acid is both efficacious and safe. Through this approach we have been able to remove the opportunistic pathogens that have proliferated whilst enabling the normal microbiome to stabilise. Peracetic acid has broad spectrum activity against bacteria, fungi and viruses with a non-specific mode of action hence there is limited risk of resistance emerging. We are looking to partner with projects looking to develop dressing for woundcare applications, particularly where wounds are infected with MDROs and biofilm. Expert in the field of UTI and vaginal mucosa including in vitro models.

Harsha Siani

• Organisation: AGA Nanotech ltd
• Position: CEO
• E-mail: hs@aga.bio
• Phone: 07580510210
• Web: www.aga.bio/